2020
Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies
Ganesh S, Cortes-Briones J, Ranganathan M, Radhakrishnan R, Skosnik PD, D’Souza D. Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies. The International Journal Of Neuropsychopharmacology 2020, 23: 559-570. PMID: 32385508, PMCID: PMC7710917, DOI: 10.1093/ijnp/pyaa031.Peer-Reviewed Original ResearchConceptsHuman laboratory studiesHealthy human volunteersPositive symptomsTHC dosePsychotomimetic effectsHuman volunteersPsychosis-like effectsNegative Syndrome ScaleProfile of symptomsCrossover studyIntravenous administrationMotor retardationHealthy individualsSyndrome ScaleSymptomsNegative syndromeSomatic concernsSubstance useConceptual disorganizationFrequent cannabisMultiple studiesMeaningful increase
2018
17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS.
Ranganathan M, D’Souza D, Cortes-Briones J, Skosnik P. 17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS. Schizophrenia Bulletin 2018, 44: s27-s27. PMCID: PMC5887318, DOI: 10.1093/schbul/sby014.066.Peer-Reviewed Original ResearchEffects of cannabidiolEarly psychosisTreatment periodPsychotic symptomsFavorable side effect profileCritical treatment periodEfficacy of cannabidiolMedication side effectsSide effect profileAnti-psychotic effectsPhase of illnessWeeks of washoutTolerable medicationsCrossover studyEffect profileAntipsychotic medicationUntreated psychosisTraditional antipsychoticsEndocannabinoid systemMetabolic parametersPsychotic illnessElectrophysiological biomarkersSide effectsTreatment engagementPotential efficacy